Browsing by Author Avall-Lundqvist, Elisabeth

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 3 of 3
Issue DateTitleAuthor(s)Citation
2017Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist)Gebski, Val; Gibbs, Emma; Lindemann, Kristina; Auranen, Annika; Avall-Lundqvist, Elisabeth; dePont Christensen, Rene; Dorum, Anne; Grenman, Seija; Hjerpe, Elisabet; Hoegberg, Thomas; Kalling, Marten; Kristensen, G; Rosenberg, Per; Skeie-Jensen, Tone; Woie, Kathrine; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreChemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist), British Journal of Cancer, vol.116, 4, 2017,pp 455-463
2011Clinical Trials in Recurrent Ovarian CancerBeale, Philip; Alberts, David; Avall-Lundqvist, Elisabeth; Brady, Mark; et al, various; Friedlander, Michael; Harter, Philipp; Pignata, Sandro; Pujade- Lauraine, Eric; Sehouli, Jalid; Tinker, Anna; Trimble, Edward; Vergote, Ignace; Central Clinical School: MedicineClinical Trials in Recurrent Ovarian Cancer, International Journal Of Gynecological Cancer, vol.21, 4, 2011,pp 771-775
2017Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit StudyBuizen, L; King, Madeleine; O'Connell, Rachel; Roncolato, Felicia; Stockler, Martin; Aotani, Enriko; Avall-Lundqvist, Elisabeth; Berek, Jonathan; Berton-Rigaud, Dominique; Donnellan, Paul; Feeney, Amanda; Friedlander, M; Heitz, Florian; Hilpert, Felix; Joly, F; Lanceley, Anne; Okamoto, Aikou; Oza, Amit; Pignata, Sandro; NH&MRC Clinical Trials Centre; Psychology; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreReducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study, The Oncologist, vol.22, 9, 2017,pp 1117-1124